Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Chief Accounting Officer | July 20, 2026 | July 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NewAmsterdam Pharma Co N.V.
Report date July 20, 2026 · Filed July 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 24,353 |
Last balance in matching sequence
After 2026-07-20 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-07-20 · Exercise / conversion · Acquired 25,000 · Balance 49,353 F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Row 2 · 2026-07-20 · Exercise / conversion · Acquired 80,000 · Balance 129,353 F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Row 3 · 2026-07-20 · Sale · Disposed 70,200 · Balance 59,153 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Row 4 · 2026-07-20 · Sale · Disposed 31,885 · Balance 27,268 F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Row 5 · 2026-07-20 · Sale · Disposed 2,915 · Balance 24,353 F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.90 · Expires 2033-05-18 | Direct | 10,000 |
Reported balance
After 2026-07-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-20 · Exercise / conversion · Disposed 25,000 · Balance 10,000 F5: The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2034-01-01 | Direct | 70,494 |
Reported balance
After 2026-07-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-20 · Exercise / conversion · Disposed 80,000 · Balance 70,494 F6: The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F5: The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
F6: The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2025 Filed Sep 5, 2025 21:06 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 18,073 | $25.09 | $453,451.57 |
DisclosureSEC source: 0000950170-25-113276 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price provided by the broker; additional information, including the price range, if any, is unavailable at the time of filing. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:43 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 18,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-113088 · ownership.xml · derivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,073 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392. F2 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. F3 · ownership.direct: The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:43 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 18,073 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-113088 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the option is EUR 1.16392. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:08 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 8,269 | $24.86 | $205,567.34 |
DisclosureSEC source: 0000950170-25-111738 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.74 per share to $24.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:29 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionRestricted Stock Unit · Derivative | 8,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-046962 · ownership.xml · derivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share. F3 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F2 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested. F2 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:29 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantRestricted Stock Unit · Derivative | 8,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-046962 · ownership.xml · derivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,269 Underlying: Ordinary Shares · 8,269 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share. F3 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F2 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested. F2 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:29 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 8,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-046962 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 23:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033927 · ownership.xml · derivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,073 Underlying: Ordinary Shares · 150,000 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392. F3 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. F2 · ownership.direct: The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 23:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 150,000 | $20.37 | $3,055,500.00 |
DisclosureSEC source: 0000950170-25-033927 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 23:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-033927 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the option is EUR 1.16392. F2 · ownership.direct: The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:21 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-003024 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on January 7, 2025 for no consideration. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:56 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 80,000 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0000950170-25-002372 · ownership.xml · derivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Ordinary Shares · 80,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 21:23 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 45,000 | $15.72 | $707,400.00 |
DisclosureSEC source: 0000950170-24-110955 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 21:23 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-110955 · ownership.xml · derivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,073 Underlying: Ordinary Shares · 45,000 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the option is EUR 1.16392. F3 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. F2 · ownership.direct: The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 21:23 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-110955 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the option is EUR 1.16392. F2 · ownership.direct: The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:26 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 150,494 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0000950170-24-001166 · ownership.xml · derivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,494 Underlying: Ordinary Shares · 150,494 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.